Durvalumab With First-Line Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology